These findings underscore a modulatory role for RBC PK (PKR) in SCD outcomes and symptoms and are supportive of investigation of the use of PKR activators in reducing the frequency of such acute pain episodes and other pathophysiology, especially in individuals with such PKLR variants (Wang et al., 2022). Here, PKLR is linked to Schnyder corneal dystrophy.